Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more
Inozyme Pharma Inc (INZY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.917x
Based on the latest financial reports, Inozyme Pharma Inc (INZY) has a cash flow conversion efficiency ratio of -0.917x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.15 Million) by net assets ($31.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inozyme Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Inozyme Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Inozyme Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inozyme Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PHOTOCURE ASA NK-50
F:PHS
|
N/A |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
0.046x |
|
West Shanghai Automotive Service Co.Ltd.
SHG:605151
|
0.058x |
|
Mold-Tek Packaging Limited
NSE:MOLDTKPAC
|
0.066x |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
0.724x |
|
Canton Strategic Holdings, Inc.
NASDAQ:CNTN
|
-0.301x |
|
Regulus Resources Inc
OTCQX:RGLSF
|
-0.015x |
|
Metemtur Yatırım Enerji Turizm ve İnşaat A.Ş.
IS:METUR
|
0.134x |
Annual Cash Flow Conversion Efficiency for Inozyme Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Inozyme Pharma Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.83 Million | $-91.91 Million | -1.589x | -215.92% |
| 2023-12-31 | $140.48 Million | $-70.67 Million | -0.503x | -3.12% |
| 2022-12-31 | $118.39 Million | $-57.76 Million | -0.488x | -10.71% |
| 2021-12-31 | $109.27 Million | $-48.15 Million | -0.441x | -93.68% |
| 2020-12-31 | $158.10 Million | $-35.97 Million | -0.228x | -140.18% |
| 2019-12-31 | $-33.22 Million | $-18.81 Million | 0.566x | -16.75% |
| 2018-12-31 | $-13.88 Million | $-9.44 Million | 0.680x | -- |